P
Piero Ruggenenti
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 348
Citations - 26899
Piero Ruggenenti is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Renal function & Kidney disease. The author has an hindex of 83, co-authored 328 publications receiving 23926 citations.
Papers
More filters
Journal ArticleDOI
Preventing microalbuminuria in type 2 diabetes.
Piero Ruggenenti,Anna Fassi,Anelja Parvanova Ilieva,Simona Bruno,Ilian Iliev,Varusca Brusegan,Nadia Rubis,Giulia Gherardi,Federica Arnoldi,Maria Ganeva,Bogdan Ene-Iordache,Flavio Gaspari,Annalisa Perna,Antonio Bossi,Roberto Trevisan,Alessandro Roberto Dodesini,Giuseppe Remuzzi +16 more
TL;DR: In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandOLapril alone decreased the incidence of micro Albuminuria to a similar extent to that of placebo.
Journal ArticleDOI
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
Piero Ruggenenti,Annalisa Perna,Giulia Gherardi,Giovanni Garini,Carmine Zoccali,Maurizio Salvadori,Francesco Scolari,Francesco Paolo Schena,Giuseppe Remuzzi +8 more
TL;DR: In non-diabetic nephropathies, ACE inhibition confers renoprotection even to patients with non-nephrotic proteinuria, and the rate of decline in GFR and the frequency of ESRF were much lower in stratum 1 than they had been instratum 2.
Journal ArticleDOI
Understanding the nature of renal disease progression
TL;DR: This article reviewed the abundant evidence in the literature that the process of reabsorption of filtered proteins activates the proximal tubular epithelium and gave rise to an inflammatory reaction that in most forms of glomerulonephritis consistently precede renal scarring.
Journal ArticleDOI
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts
Brad C. Astor,Kunihiro Matsushita,Ron T. Gansevoort,Marije van der Velde,Mark Woodward,Andrew S. Levey,Paul E. de Jong,Josef Coresh,Meguid El-Nahas,Kai-Uwe Eckardt,Bertram L. Kasiske,Jackson T. Wright,Lawrence J. Appel,Tom Greene,Adeera Levin,Ognjenka Djurdjev,David C. Wheeler,Martin J Landray,John N. Townend,Jonathan Emberson,Laura E Clark,Alison M. MacLeod,Angharad Marks,Tariq Ali,Nicholas Fluck,Gordon Prescott,David H. Smith,Jessica R. Weinstein,Eric S. Johnson,Micah L. Thorp,Jack F.M. Wetzels,Peter J. Blankestijn,A D van Zuilen,Vandana Menon,Mark J. Sarnak,Gerald J. Beck,Florian Kronenberg,Barbara Kollerits,Marc Froissart,Bénédicte Stengel,Marie Metzger,Giuseppe Remuzzi,Piero Ruggenenti,Annalisa Perna,H. J. Lambers Heerspink,Barry M. Brenner,Dick de Zeeuw,Peter Rossing,Hans-Henrik Parving,Priscilla Auguste,Kasper Veldhuis,Yaping Wang,Laura Camarata,Beverly Thomas,Tom Manley +54 more
TL;DR: Lower eGFR and more severe albuminuria independently predict mortality and ESRD among individuals selected for CKD, with the associations stronger for E SRD than for mortality.
Journal ArticleDOI
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
Piero Ruggenenti,Annalisa Perna,Giacomina Loriga,Maria Ganeva,Bogdan Ene-Iordache,Marta Turturro,Maria Lesti,Elena Perticucci,Ivan Nediyalkov Chakarski,Daniela Leonardis,Giovanni Garini,Adalberto Sessa,Carlo Basile,Mirella Alpa,Renzo Scanziani,Gianbattista Sorba,Carmine Zoccali,Giuseppe Remuzzi +17 more
TL;DR: In patients with non-diabetic proteinuric nephropathies receiving background ACE-inhibitor therapy, no additional benefit from further blood-pressure reduction by felodipine could be shown.